Physician profile
Lissa V Rivero
NPI 1528028081
$5,212.07
in general payments reported to CMS, 2019-2025
29 companies · $1,876 in 2025
The $1,876 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $175 · 2021: $447 · 2022: $545 · 2023: $896 · 2024: $1,157 · 2025: $1,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,928.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $492.06 | 2023-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Horizon Therapeutics Plc | $476.42 | 2020-2023 | Tepezza |
| Amgen INC. | $451.52 | 2019-2025 | Tepezza |
| Alcon Vision LLC | $444.15 | 2019-2025 | Tryptyr, Hydrus Microstent, Rocklatan |
| Tarsus Pharmaceuticals, INC. | $441.61 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $392.14 | 2021-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $390.62 | 2019-2024 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $375.21 | 2024-2025 | Tecnis Iol |
| Ani Pharmaceuticals, INC. | $311.13 | 2023-2025 | Purified Cortrophin Gel |
| Harrow Eye, LLC | $240.34 | 2025 | Vevye |
| Coopervision INC. | $165.81 | 2022-2025 | Clariti Contact Lens, Myday Contact Lens |
| Ocular Therapeutix, INC. | $125.98 | 2024 | Dextenza |
| Spark Therapeutics, INC. | $121.85 | 2021 | |
| Rxsight INC | $107.08 | 2022 | |
| Oyster Point Pharma, INC. | $99.06 | 2023 | Tyrvaya |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $93.31 | 2025 | Omni Surgical System |
| Lombart Brothers, INC. | $92.72 | 2020 | |
| Samsara Vision | $63.90 | 2022 | |
| Lkc Technologies, INC. | $60.79 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.12 | 2022 | |
| Dutch Ophthalmic, USA | $42.34 | 2024 | Eva, Combined Machine, Tissueblue |
| Regeneron Healthcare Solutions, INC. | $31.76 | 2019-2021 | |
| Dompe US, INC. | $28.57 | 2025 | Oxervate |
| Biotissue Holdings INC. | $28.49 | 2025 | |
| Abb Con-Cise Optical Group LLC | $25.88 | 2024 | Contact Lens, Spectacle Lenses |
| Novartis Pharmaceuticals Corporation | $17.09 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.84 | 2020 | |
| Alimera Sciences, INC. | $16.28 | 2020 | |
| Shire North American Group INC | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lissa Rivero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.